111 related articles for article (PubMed ID: 12494768)
61. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
Eischen CM; Woo D; Roussel MF; Cleveland JL
Mol Cell Biol; 2001 Aug; 21(15):5063-70. PubMed ID: 11438662
[TBL] [Abstract][Full Text] [Related]
62. RNA targeting in cancer cells.
Ceriani MC; Bevilacqua AM; Asnaghi L; Nicolin A
Suppl Tumori; 2002; 1(6):S22-4. PubMed ID: 12658898
[No Abstract] [Full Text] [Related]
63. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B
Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685
[TBL] [Abstract][Full Text] [Related]
64. Nuclear bcl-2 staining in tumors.
Drachenberg CB; Ioffe OB; Castellani RJ; Papadimitriou JC
Am J Clin Pathol; 1997 Oct; 108(4):479. PubMed ID: 9322602
[No Abstract] [Full Text] [Related]
65. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
[TBL] [Abstract][Full Text] [Related]
66. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
Hu Q; Bally MB; Madden TD
Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
[TBL] [Abstract][Full Text] [Related]
67. Alternative splicing regulates the nuclear or cytoplasmic localization of dystrophin Dp71.
González E; Montañez C; Ray PN; Howard PL; García-Sierra F; Mornet D; Cisneros B
FEBS Lett; 2000 Oct; 482(3):209-14. PubMed ID: 11024462
[TBL] [Abstract][Full Text] [Related]
68. Antisense oligonucleotides complementary to Bax transcripts reduce the susceptibility of B-cell chronic lymphocytic leukaemia cells to apoptosis in a bcl-2 independent manner.
Pepper C; Thomas A; Hoy T; Bentley P
Leuk Lymphoma; 2002 Oct; 43(10):2003-9. PubMed ID: 12481899
[TBL] [Abstract][Full Text] [Related]
69. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
70. Antisense oligonucleotides targeting c-fos mRNA inhibit rheumatoid synovial fibroblast proliferation.
Morita Y; Kashihara N; Yamamura M; Okamoto H; Harada S; Kawashima M; Makino H
Ann Rheum Dis; 1998 Feb; 57(2):122-4. PubMed ID: 9613344
[TBL] [Abstract][Full Text] [Related]
71. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.
Sazani P; Kang SH; Maier MA; Wei C; Dillman J; Summerton J; Manoharan M; Kole R
Nucleic Acids Res; 2001 Oct; 29(19):3965-74. PubMed ID: 11574678
[TBL] [Abstract][Full Text] [Related]
72. Introns and Their Therapeutic Applications in Biomedical Researches.
Haddad-Mashadrizeh A; Mirahmadi M; Taghavizadeh Yazdi ME; Gholampour-Faroji N; Bahrami A; Zomorodipour A; Moghadam Matin M; Qayoomian M; Saebnia N
Iran J Biotechnol; 2023 Oct; 21(4):e3316. PubMed ID: 38269198
[TBL] [Abstract][Full Text] [Related]
73. All-Atom MD Predicts Magnesium-Induced Hairpin in Chemically Perturbed RNA Analog of F10 Therapeutic.
Melvin RL; Gmeiner WH; Salsbury FR
J Phys Chem B; 2017 Aug; 121(33):7803-7812. PubMed ID: 28745046
[TBL] [Abstract][Full Text] [Related]
74. Conditional control of alternative splicing through light-triggered splice-switching oligonucleotides.
Hemphill J; Liu Q; Uprety R; Samanta S; Tsang M; Juliano RL; Deiters A
J Am Chem Soc; 2015 Mar; 137(10):3656-62. PubMed ID: 25734836
[TBL] [Abstract][Full Text] [Related]
75. Delivery of oligonucleotides with lipid nanoparticles.
Wang Y; Miao L; Satterlee A; Huang L
Adv Drug Deliv Rev; 2015 Jun; 87():68-80. PubMed ID: 25733311
[TBL] [Abstract][Full Text] [Related]
76. Noncoding RNAs in Neurodegenerative Diseases.
Rege SD; Geetha T; Pondugula SR; Zizza CA; Wernette CM; Babu JR
ISRN Neurol; 2013; 2013():375852. PubMed ID: 23738143
[TBL] [Abstract][Full Text] [Related]
77. Modulation of 5' splice site selection using tailed oligonucleotides carrying splicing signals.
Gendron D; Carriero S; Garneau D; Villemaire J; Klinck R; Elela SA; Damha MJ; Chabot B
BMC Biotechnol; 2006 Jan; 6():5. PubMed ID: 16412215
[TBL] [Abstract][Full Text] [Related]
78. Modulation of alternative splicing by antisense oligonucleotides.
Sazani P; Kole R
Prog Mol Subcell Biol; 2003; 31():217-39. PubMed ID: 12494768
[No Abstract] [Full Text] [Related]
79. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.
Sazani P; Kole R
J Clin Invest; 2003 Aug; 112(4):481-6. PubMed ID: 12925686
[TBL] [Abstract][Full Text] [Related]
80. RNA modulation, repair and remodeling by splice switching oligonucleotides.
Kole R; Williams T; Cohen L
Acta Biochim Pol; 2004; 51(2):373-8. PubMed ID: 15218534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
